Spectinamides: A challenge, a proof, and a suggestion

Trends in Microbiology

Volumn 22, Issue 4, 2014, Pages 170-171

  Viveiros, Miguel ^a   Pieroni, Marco ^b  

^a INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BEDAQUILINE; ISONIAZID; NITROGEN; RIFAMPICIN; RNA 16S; SPECTINAMIDE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIAL CELL; BACTERIAL GROWTH; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; BINDING SITE; CRYSTAL STRUCTURE; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; INHIBITION KINETICS; LATENT VIRUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RESIDUE ANALYSIS; SHORT SURVEY; TUBERCULOSIS;

AMIDES; ANIMALS; ANTITUBERCULAR AGENTS; DRUG DESIGN; MODELS, MOLECULAR; MYCOBACTERIUM TUBERCULOSIS; SPECTINOMYCIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84897434951     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2014.02.008     Document Type: Short Survey

References (10)

1. Lee R.E., et al. Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. Nat. Med. 2014, 20:152-158.
2. Comas I., et al. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat. Genet. 2013, 45:1176-1182.
3. Pieroni M., et al. Pyrido[1,2- a]benzimidazole-based agents active against tuberculosis (TB), multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB. ChemMedChem 2011, 6:334-342.
4. Onajole O.K., et al. Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains. J. Med. Chem. 2013, 56:4093-4103.
5. Zumla A., et al. Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 2013, 12:388-404.
6. Swinney D.C., Anthony J. How were new medicines discovered?. Nat. Rev. Drug Discov. 2011, 10:507-519.
7. Viveiros M., et al. Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs. Expert Rev. Anti Infect. Ther. 2012, 10:983-998.
8. Balganesh M., et al. Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates. Antimicrob. Agents Chemother. 2012, 56:2643-2651.
9. Machado D., et al. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS ONE 2012, 7:e34538.
10. Adams K.N., et al. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 2011, 145:39-53.